5% in the drinking water.26 All other methods are described in the Supporting Material. Twenty-four-week-old tx-j mice had lower body weights and higher liver/bodyweight ratios than control C3H mice (Table 1). Mean Selleck Lumacaftor hepatic Cu concentration was more than 30 times increased in the tx-j mice and was associated with
marked lobular and portal inflammation, with ∼6-fold increase in serum alanine aminotransferase (ALT) levels and increased liver Tnf-α transcript levels. There were no differences in hepatic iron levels between the groups. Liver histopathology of tx-j mice at 24 weeks of age showed lymphocytic lobular and portal infiltrates and perisinusoidal fibrosis (Fig. 1). The oral provision of PCA to tx-j mice from age 12 to 24 weeks resulted in 50% reduction of hepatic Cu and serum ALT levels, 90% reduction in liver Tnf-α expression, and concomitant improvements of both lobular and portal infiltration, whereas betaine treatment had no effect on Tnf-α transcripts or serum ALT in tx-j mice, but significantly lowered mean hepatic Cu levels in control mice by 61% and nonsignificantly lowered mean hepatic Cu levels by 30% while reducing lobular inflammation (Table 1). Hepatocyte and nuclear diameters and their ratios and hepatocyte nuclear areas were increased in tx-j mice, but were unchanged by either PCA or betaine. The transcript levels of
selected genes related to ER stress (glucose-regulated protein Idoxuridine 78 [Grp78]), lipogenesis (sterol regulatory check details element-binding protein [Srebp1c]), and fatty acid β oxidation (peroxisome proliferator-activated receptor α [Pparα] and carnitine palmitoyl transferase 1A [Cpt1A]), and protein levels of SREBP1c and PPARα were each lower in untreated tx-j than in C3H mice (Fig. 2). PCA further down-regulated Srebp1c and Pparα transcript levels and protein levels of GRP78 and CPT1A in tx-j mice. Betaine down-regulated the transcript levels of Grp78, Pparα, and Cpt1A in the control mice and Cpt1A in tx-j mice, whereas both transcript and protein levels of SREBP1c, PPARα,
and CPT1A were each lower in betaine-treated tx-j mice than in betaine-treated control mice. Liver S-adenosylmethionine (SAM) levels were similar in the untreated groups, whereas SAH levels were increased and SAM to SAH ratios were lower in the tx-j mice versus control mice (Fig. 3A-C). Although SAHH activity was similar in both untreated groups (Fig. 3D), both SAHH gene and protein expressions were decreased in the tx-j mice (Fig. 3F). DNA methyltransferase 1 (Dnmt1) transcripts were up-regulated, Dnmt3a transcripts were similar, and Dnmt3b transcripts were down-regulated in tx-j mice (Fig. 4A-C). According to dot blot analysis, global DNA methylation was lower in tx-j than in C3H mice (Fig. 5). PCA treatment reduced Tnf-α transcripts by 10-fold (Table 1) and increased SAHH activity in tx-j mice (Fig.
She also reported blurred vision. Examination revealed drooping buy PLX4032 of both eyelids. Computed tomography and Magnetic resonance imaging of the head did not detect abnormal findings. Chest CT showed right lower lobe pneumonia, no
thymoma was present. Subsequent positive Neostigmine test confirmed a diagnosis of myasthenia gravis (MG). Conclusion: In conclusion, our case report together with other evidence, suggests the association between CD and MG is potential instead of coincidental. Further study is needed to investigate the exact coexistent mechanism between these two diseases. Key Word(s): 1. Crohn’s disease; 2. Myasthenia Gravis; 3. Mechanism; 4. Association; Presenting Author: CHENJIAN YONG Corresponding Author: CHENJIAN YONG Affiliations: The people’s hospital of Jianxi Province Objective: To explore the effects of Lipopolysaccharide (LPS)/inhibitor of calcium/ calm- odulin-dependent protein kinaseII (KN62) pretreatment on colitis of BALB/C mice animal model
induced by trinitrobenzene sulfonic RXDX-106 acid. Methods: BALB/C mice were randomly assigned to four groups: normal control group (NC group), model control group (UC group), LPS group and KN62 group. Except that the normal control group was administered intracolonically with saline, the other groups were administered intracolonically with Trinitrobenzene sulfonic acid ethanol solution to construct colitis model. Mice of the LIProupalso received intraperitoneal injection of Lipopolysaccharide, KN62 group received intraperitoneal injection of KN62, while the model control group received intraperitoneal injection of saline. The disease activity index (DAI) and histological index (HI) were calculated, the expression of IL-6mRNA in the intestinal mucosa was measured by reverse transcription Polymerase
Chain Response (RT-PCR), the expression level of Mouse MHC-II molecules in the Lamina propria. was measured by Flow cytometry. Results: From the results we can find that the DAI score, HI score, Isotretinoin the expression of IL-6mRNA, the level of MHC-II with NC group compared with UC group had statistical difference (P < 0.05), LPS group compared with UC group had statistical difference (P < 0.05) KN62 group compared with UC group had statistical difference (P < 0.05). Conclusion: Treatment with KN62(25 ng/mouse), DAI, HI, the expression of IL-6mRNA in the intestinal mucosa and the expression level of Mouse MHC-II molecules in the Lamina propria of mice with experimental colitis decreased indicates KN62 can attenuate the inflammation and be useful for protection to host. Key Word(s): 1. TNBS; 2. Inflammatory bowel; 3. Lipopolysaccharide; Presenting Author: XIAOSAN ZHU Additional Authors: YICHEN DAI, ZHANGXING CHEN, YUANYUAN LIN Corresponding Author: XIAOSAN ZHU Affiliations: The 174th Hosptial of the PLA Objective: To study the clinical and endoscopic characteristics of ulcerative colitis.
When such data become available,
evidence-based guidelines for the diagnosis and management of RBDs will transform from a long-due quest to a reality. The authors stated that they had no interests which might be perceived as posing a conflict or bias. “
“This chapter contains sections titled: Biosynthesis Structure and function Prothrombin deficiency Laboratory diagnosis Clinical manifestations Therapeutic aspects Conclusion References “
“Haemophilia A is associated with recurrent joint bleeding which leads to synovitis and debilitating arthropathy. Coagulation factor VIII level is an important determinant of selleck chemicals llc bleed number and development of arthropathy . The aim of this study was to compare the haemophilia joint health score (HJHS) and Gilbert score with severity, age, thrombin generation (TG) and underlying mutation in a haemophilia A cohort which had minimal access to haemostatic replacement therapy. Ninety-two haemophilia A individuals were recruited from Pakistan. Age, age at first
bleed, target joints, haemophilic arthropathy joints, HJHS and Gilbert score were recorded. A strong correlation was found between HJHS and Gilbert score (r = 0.98), both were significantly higher in severe CHIR-99021 cost (n = 59) compared with non-severe (n = 29) individuals before the age of 12 years (P ≤ 0.01) but not thereafter. When individuals were divided according to developmental age (<12 years, 12–16 years and >16 years), both HJHS and Gilbert score were significantly lower in the youngest group (P ≤ 0.001), there was no difference between 12–16 years and >16 years. In severe individuals there was no correlation between in vitro TG and joint score, whereas in non-severe individuals there was a weak negative correlation. In the severe
mafosfamide group, no significant difference was observed for either joint score according to the underlying mutation type (inversion, missense, nonsense, frameshift). In this cohort of haemophilia A individuals with minimal access to haemostatic treatment, haemophilic arthropathy correlated with severity and age; among severe individuals, joint health scores did not relate to either the underlying mutation or in vitro TG. “
“Despite recent advances including new therapeutic options and availability of primary prophylaxis in haemophiliacs, haemophilic synovitis is still the major clinical problem in significant patient population worldwide. We retrospectively reviewed our 10-year experience with Y-90 radiosynovectomy to determine the outcome in the knee joints of patients with haemophilic synovitis.
No patients in placebo group presented a clinically relevant decrease in HVPG, while 4 patients (36%) in the simvastatin group reached this endpoint (p=0.045). Considering only patients with severe portal hypertension at baseline (HVPG ≥ 12mmHg, n=13), the decrease was achieved by 50% of them, all patients in simvas-tatin group. The baseline mean AzBF were 501.2 ± 385 mL/ min in placebo group and 532.7 ± 365 mL/min in simvastatin group, and present a decrease of 19% and 38%, respectively, at the end of the protocol (p=0.02). Although both HVPG and AzBF reduced after simvastatin use, the correlation between the methods was weak (r=0,39). Two thirds of the patients were taking nonselective
beta adrenergic blockers and these drugs did not interfere with simvastatin hemodynamic effect. Moderate and severe adverse events did not occur in
simvastatin group. CONCLUSION: Decitabine solubility dmso Simvastatin seems to be safe in liver cirrhosis and can significantly lower portal pressure. This effect is more evident in patients with severe portal hypertension, precisely the group most in need of prevention of its complications. The correlations between the HVPG and the AzBF is weak probably because the azygos system is only one of several drainage pathways in portal hypertension. These results reinforce the trend of incorporating statins in the therapeutic arsenal of cirrhotic portal hypertension. Disclosures: The following people have nothing to disclose: selleckchem Priscila P. Flores, Guilherme F. Rezende, Ubiratan Cassano, Monica Soldan BACKGROUND AND AIMS: The increase of intrahepatic availability of nitric oxide induced by statins Teicoplanin makes this drugs a potential option for the treatment of portal hypertension. This clinical trial was designed to evaluate the effects of simvastatin on the hepatic venous pressure gradient (HVPG) and on the azygos vein blood flow (AzBF) in cirrhotic patients. METHODS: A prospective, randomized, controlled, triple-blind trial with simvastatin and placebo was conducted, including patients with
cirrhosis and portal hypertension detected by abdominal ultrasound with color Doppler flowmetry or upper digestive endoscopy. Placebo or simvastatin (40 mg) was given daily; HVPG was determined by hepatic vein catheterization and AzBF was measured by color Doppler echoendoscopy (EUS-Cd), both procedures performed at the beginning and after three months of treatment. The main endpoint was a decrease in HVPG of at least 20% from baseline or to ≤ 12 mm Hg after treatment, considered clinically relevant. The correlation between HVPG and AzBF was also tested. RESULTS: Thirty four patients were prospectively enrolled in the study and 22 of them completed the 3 month-protocol. The two groups of treatment were similar at baseline in terms of clinical aspects, liver disease and portal hypertension severity.
Liver stiffness was measured by transient elastography at baseline and after 12 months of treatment in 20 nucleos(t)ide-naïve patients who started entecavir within 3 months after study entry. Results: Twenty (40%) patients were classified as F1, 10 (20%) as F2, 5 (10%) as F3, and 15 (30%) as F4 (cirrhosis). Median liver stiffness (interquartile range) was 7.0 kPa (5.6–9.4), this website 9.8 kPa (5.6–14.7), 9.8 kPa (7.6–12.9), and 17.3 kPa (8.2–27.6) in fibrosis stages F1 to F4, respectively. Liver stiffness significantly correlated with fibrosis stage (r = 0.46; P = 0.0014). Of the patients who
started entecavir, median liver stiffness significantly decreased from 11.2 kPa (7.0–15.2) to 7.8 kPa (5.1–11.9; P = 0.0090) during 12 months of treatment. Median levels of amino-terminal peptide of type III procollagen and type IV collagen 7S domain in serum significantly decreased from 0.9 (0.6–1.3) to 0.6 (0.5–0.7) U/mL (P = 0.0010) and from 5.0 (4.4–6.7) to 3.9 (3.2–4.4) ng/mL (P = 0.015), respectively. Vorinostat Conclusion: Liver stiffness measurement can be useful for monitoring regression of liver fibrosis during entecavir treatment in patients with chronic hepatitis B virus
“While the recent inclusion of direct-acting antiviral (DAA) therapies has recently improved the
standard of care (SOC) for patients with hepatitis C virus (HCV) genotype 1 infection; the remaining limitations of efficacy, side effects, and high costs remain challenges for improving therapy. A foreseeable goal is an exclusively orally administered treatment regimen, free of interferon (IFN) and IFN-associated side effects. While the current SOC for patients with genotype 1 infection is composed of Buspirone HCl pegylated IFN alpha with ribavirin (RBV) and either telaprevir or boceprevir, treatment is anticipated to improve by the inclusion of a second-generation protease inhibitor and/or DAAs targeting the viral polymerase or NS5A protein, and eventually removal of IFN. A remaining arm of anticipated future treatment is the guanosine nucleotide analog, RBV. Recent results with next-generation DAAs including sofosbuvir have highlighted RBV’s role in the upcoming anti-HCV regimens.[3, 4] Even though RBV has been employed in treating hepatitis C for more than 20 years, the primary mechanism of its action is still unclear. This lack of clarity is hindered by the current state-of-the-art Huh7 cell-based models of HCV infection poorly reflecting the in vivo activity of RBV at clinical concentrations. There is evidence supporting multiple mechanisms of RBV’s anti-HCV activity (Fig. 1).
Key Word(s): 1. bowel obstruction; 2. diagnosis; 3. biomarkers; 4. physical examination; Presenting Author: JOHNSON MARIAANTONY Corresponding Author: JOHNSON MARIAANTONY Affiliations: Dr.
selleck inhibitor MGR Medical Unversity Objective: Obstructive jaundice due to Bile Duct Tumor Thrombi is an uncommon presenting feature of Hepatocellular Carcinoma (HCC) reported in about 2–9% (Okuda &Nakashima series) and 12% (Hong Kong study group) of cases respectively. Only a few studies have examined the outcome of hepatectomy in this subset of patients. Aim: To evaluate the outcome of hepatectomy for non- fibrolamellar- type HCC with obstructive jaundice due to bile duct tumor thrombi in non-cirrhotic liver. Methods: From 1995 to 2007, out of 156 HCC patients, 19 (12.1%) with
non-fibrolmellar- type HCC with obstructive jaundice due to bile duct tumor thrombi in non-cirrhotic learn more liver, who underwent hepatectomy were retrospectively analyzed. HBsAg, Anti HCV Ab and AFP were positive in 3 (15.7%), one (5.2%), and 13 (68.4%) cases respectively. The operative procedures included, right hepatectomy with thrombectomy through choledochotomy and T-tube drainage (n = 8), extended right hepatectomy combined with extrahepatic bile duct excision (n = 3), left hepatectomy (n = 6), extended left hepatectomy (n = 1) and left lateral segmentectomy (n = 1). Results: The diameter of primary Dimethyl sulfoxide tumor ranged from 5 to 13 cm. Biliary tumor thrombi were located in the right and left hepatic ducts in two, free floating in the common bile duct in 9, and extended across the confluence of the right and left hepatic ducts in 8 patients respectively according to Satoh’s classification. Portal vein invasion were found in 4 patients (right branch n = 1, left branch n = 1, right posterior branch n = 1, right branch to stem n = 1). Postoperative morbidity was 31.5% (n = 6), which included bile leak in 4 (21.05%) patients. One patient died of postoperative liver failure (mortality rate 5.2%). The tumor recurrence rates were intrahepatic in 68.4%, extrahepatic in 21.0% and both intrahepatic and extrahepatic in
10.5%. The 1-; 3- and 5-year survival rates were 78.9%, 47.3% and 10.5% respectively with a median survival time of 24.8 months. Conclusion: Presence of bile duct tumor thrombi in HCC patients should not be considered as advanced disease or inoperable lesion. When technically feasible, a formal hepatic resection is the first-line treatment option in a subset of HCC patients with obstructive jaundice due to bile duct tumor thrombi in non-cirrhotic liver with significantly large-sized tumors. It can achieve better quality of life with significant improvement in both disease-free and overall survival. Key Word(s): 1. HCC; 2. Non-cirrhotic liver; 3. Tumor thrombi; 4. Hepa; Presenting Author: JOHNSON MARIAANTONY Corresponding Author: JOHNSON MARIAANTONY Affiliations: Dr.
Transcription of the Cyp8b1 gene was tremendously induced upon colesevelam treatment in the wildtype
but not in the knockdown animals (Fig. 3C). These results show that LRH-1 is a critical transcription factor for adequate up-regulation of Cyp7a1 and Cyp8b1 transcription under conditions of bile salt sequestration. In addition, the apparent paradoxical behavior observed for Cyp7a1 transcription in the LRH-1-KD mice suggest that two LRH-1-dependent, but mechanistically different, mechanisms are involved in the transcriptional regulation of Cyp7a1 expression. A previous study in mice deficient for intestinal Lrh-1 showed a reduction of intestinal Fgf15 mRNA expression, suggesting selleck kinase inhibitor that intestinal LRH-1 directly or indirectly regulates Fgf15 expression.31 Colesevelam did not alter intestinal Lrh-1 expression in wildtype mice Buparlisib mouse but did suppress Shp and Fgf15 expression (Fig. 3D), which is consistent with previous findings.33 Intestinal Shp levels were significantly reduced in LRH-1-KD mice on and off colesevelam (Fig. 3D). Interestingly, we also found a tremendous reduction in Fgf15 mRNA levels in Lrh-1-KD mice on and off colesevelam,
indicating that (intestinal) Lrh-1 regulates the expression of the Fgf15 gene. To further support this relationship, we tested whether LRH-1 would increase expression of FGF19, the human ortholog of murine FGF15, in DLD cells. Transduction of DLD cells with increasing amounts of recombinant LRH-1 encoding adenoviral particles (Supporting Fig. 3A,B) caused a dose-dependent increase in FGF19 mRNA expression (Supporting Fig. 3C). These data indicate that LRH-1 indeed induces Fgf15/19 expression.
We tested whether altered Cyp7a1 expression Olopatadine in colesevelam-treated LRH-1-KD animals also had physiological consequences. Knockdown of LRH-1 did not cause significant alterations in bile flow rate and only tended to reduce biliary bile salt output (Fig. 4A,B). Treatment with colesevelam did not affect bile flow, but reduced biliary bile salt output in both WT mice and LRH-1-KD mice (Fig. 4A,B), in agreement with previous studies from our laboratory.33 In agreement with the observed increase in Cyp7a1 expression levels (Fig. 3C), knockdown of LRH-1 caused a modest increase (+10%) of fecal bile salt output (Fig. 4C). As expected, sequestrant treatment led to a massive induction (+272%) of fecal bile salt output in WT mice. Because colesevelam was given for 2 weeks, a new steady state is established in which fecal loss depicts enhanced bile acid synthesis. In LRH-1-KD mice there was no increase in fecal bile acid output after 2 weeks (Fig. 4C), indicating that LRH-1-KD mice cannot up-regulate bile acid synthesis during colesevelam treatment. As Cyp8b1 expression was also dysregulated in LRH-1-KD mice, we expected that LRH-1 knockdown combined with sequestrant would have profound effects on bile salt composition. Supporting Fig.
 To eliminate HCV, which establishes chronic infection in ~80% of infected individuals, interferon (IFN)-based treatments have been developed. The treatment of first choice at present for IFN-naïve patients of HCV genotype 1 with high viral load in Japan is pegylated interferon (PEG IFN), ribavirin
(RBV) and telaprevir (TVR) triple therapy, if it can be tolerated. Although the sustained virological response (SVR) rate is much improved by the triple therapy, it is poorly tolerated due to a number of adverse events. Anemia is often a critical barrier to successful treatment for chronic hepatitis C patients on IFN therapy with RBV, forcing reduction or discontinuation of RBV administration. To overcome this obstacle, several groups reported employment SB203580 manufacturer of human recombinant erythropoietin (EPO) administration to alleviate anemia and thereby complete the therapy without RBV reduction in patients under IFN/RBV or PEG IFN/RBV combination therapy.[3-8] Most of the reports describe the successful role of EPO as an alternative to RBV dose reduction, and meta-analysis demonstrates that EPO administration can considerably enhance SVR with no adverse event due to EPO. In triple therapy, Selumetinib ic50 anemia develops more frequently than in PEG IFN/RBV combination therapy, consequently resulting in poor adherence to RBV.[10,
11] Thus far, little is known about the efficacy of EPO to RBV-induced anemia in the triple therapy. In the present study, we examined whether EPO administration can alleviate anemia in hepatitis C patients on IFN therapy receiving both RBV and TVR, as observed in the PEG IFN/RBV combination therapy. The patients were given human recombinant epoetin-α at a dose of 12 000 or 24 000 IU/week, which is a relatively low dose compared with those used in previous reports, determined according
to the hemoglobin (Hb) decline from the baseline. The average adherence of the patients with EPO administration to RBV during the triple therapy phase was 97.5%, which was clearly higher than that of the phase III study of triple therapy,[10, 11] and no adverse event was observed. These findings indicate that low-dose EPO administration facilitates RBV adherence and can Mirabegron be a favorable alternative to RBV dose reduction. THE OBJECTIVE OF this study was to determine the safety of EPO administration and find whether it could prevent dose reduction of RBV due to anemia in triple therapy. Twenty-two patients (15 men and seven women, mean age of 56 years [range, 31–70]) with HCV genotype 1 infection and 5.0 log10 IU/mL or higher HCV RNA level were enrolled. All patients gave their informed consent before participating in the study. The study was approved by the ethics committee of Osaka National Hospital and conducted in accordance with good clinical practice and the Declaration of Helsinki. All patients received PEG IFN-α-2b (PegIntron; MSD, Tokyo, Japan) at a dose of 1.5 μg/kg/week s.c.
5 vs. 6.4; P<0.05). Bioenergetics at 1 wk deteriorated
in NRS compared to responders, P>0.05 probably due to small sample size. Conclusions: Baseline cellular bioenergetics seems a promising biomarker in ALD patients for AH diagnosis and predicting response to CS. More data are needed before accepting use of this simple biomarker in clinical practice. Bioenergetics in peripheral monocytes: Oligomycin inhibits ATP linked, FCCP uncouples, Antimycin complete inhibitor, PMA stimulates oxidative burst. Disclosures: Victor Darley-Usmar – Advisory Committees or Review Panels: Seahorse BIoscience The following people have nothing to disclose: Ashwani K. Singal, Philip A. Kramer, Saranya Ravi, Toni Seay, Balu Chacko, Degui Zhi Background: Chronic alcohol consumption increases intestinal permeability by PF-02341066 in vivo disrupting tight junctions that preserve intestinal epithelial integrity. Through these impaired tight
junctions, the viable bacteria and/or bacterial products from the gut lumen can translocate to the liver via the portal vein and trigger an inflammatory response that contributes to the progression of liver disease. We have previously demonstrated that betaine feeding attenuates steatosis and other features of hepatic liver injury in ethanol-fed rodents (Kharbanda et al, J of Hepatology, 2007). Here, we investigated whether betaine feeding could mitigate ethanol-induced damage to the intestinal epithelium Nutlin-3a datasheet and maintain the gut barrier function to decrease bacteria/bacterial product translocation Bay 11-7085 and thereby attenuate liver damage. Methods: C57Bl/6 mice were chronically pair-fed ethanol or control liquid diets with or without 1.5% betaine supplementation. At sacrifice, intestinal samples were harvested and the ileum segments were examined. Results: RT-PCR and immu-noblotting showed ethanol consumption decreased occludin mRNA and protein levels, while giving betaine supplementation
to the ethanol fed mice prevented this decrease. Immuno-fluorescent staining revealed that ethanol feeding reduced the distribution of both occludin and claudin-1 between cells in the ileal epithelium. Feeding a betaine-supplemented ethanol diet prevented such decrease in the distribution of these tight junction proteins. RT-PCR analysis further showed ethanol feeding decreased intestinal trefoil factor (ITF) which plays an important role in epithelial protection, while increasing the expression of two inflammatory cytokines, tumor necrosis factor alpha (TNF-α) and monocyte chemoattractant protein (MCP-1). The effects of ethanol on ITF, TNF-α and MCP-1 mRNA expression were reversed in the ileum of mice fed the betaine-supplemented ethanol diet. Conclusion: Our findings indicate betaine supplementation attenuates the ethanol-induced intestinal barrier dysfunction by preserving the distribution of tight junction proteins and promoting protective factors while mitigating the inflammatory response.
16 We also explored an alternative model by which the treatment effectiveness in blocking viral production, ε, can change over time during therapy: (2) Let tend denote the time when
the last dose was taken and t1 the length of the delay until drug effectiveness starts decreasing. For qd and bid regimens tend =13 days and tend =13.5 days, respectively. Assuming that the drug effectiveness is related to the intracellular drug concentration C(t) by an Emax model18 of the form: (3a) Model parameters were obtained by a maximum likelihood method using MONOLIX version 3.1 (http://software.monolix.org), a software program based on a stochastic approximation expectation–approximation (SAEM) algorithm.19 After the population BI 2536 order parameters and the between-subject variabilities were found, the estimated parameters for each individual were deduced using empirical Bayes estimates.20 Thus, all dosing groups were analyzed simultaneously and the parameters have the same distributions, regardless of the dosing groups. For each parameter, we report the population estimates and standard errors, as well as the first and third quartiles of the individual NVP-LDE225 estimates (when the sample size was large enough). One subject (#92206) did
not respond to treatment and therefore was not included in the final analysis. In order to reduce the number of parameters to be estimated in the VE model, c was fixed to 6 d−1.15 Moreover, t0 was determined empirically as the last sampling time before the viral load declined by more than 0.2 log10 and did not increase afterward above baseline, or before two Clomifene consecutive decreasing HCV RNA measurements. Two covariates were included in the model to study their impact on the viral kinetic parameters. The first covariate was the treatment dosing regimen group. Except for the
determination of the final treatment effectiveness (ε2), the qd and bid groups were treated together. Also, we considered a second covariate distinguishing patients having or not having a monotonic viral decline throughout the treatment period. For that purpose we computed for each patient by linear regression the slope, s2, of the HCV RNA measurements between t = 4 days and t = 13 days, a period typically considered to be part of the second phase of viral decline (Supporting Table 1). A t-test was used to assess whether s2 was significantly different than 0. If s2 was not significantly (P > 0.1) different than 0, the patient was said to have a flat second-phase response. By this criterion, 52% (16/31) of the patients had a flat second-phase response, with no difference in distribution among dosing regimens (Supporting Table 1). More details on the fitting method and statistical analysis of the model are given in the supporting materials. We first fitted the data using the standard (CE) model of viral dynamics (Eqs. 1 and 3a,b) (Table 1).